Abstract. Thymocyte selection-associated high mobility group box (TOX) genes represent a novel family of genes. Deregulated expression of TOXs has been reported in a variety of cancer types, including lung cancer. It has also been reported that TOXs are crucial regulators of the immune system. The present study systematically evaluated the prognostic values of TOX family members using a set of publicly accessible databases, including Oncomine, Kaplan-Meier plotter and cBioPortal. It was revealed that TOX expression profiles differed between lung cancer and normal tissues, and high expression of TOX mRNAs generally predicted improved survival outcomes. Notably, TOX3 expression was significantly increased in lung adenocarcinoma, compared with other pathological subtypes of lung cancer. Survival analysis demonstrated that elevated TOX3 expression was significantly associated with improved progression-free and overall survival in patients with lung adenocarcinoma. Furthermore, correlation analysis indicated that TOX3 expression was negatively correlated with the expression of programmed death-1 receptor (PD-1), PD-ligand 1 and Hepatitis A virus cellular receptor 2 in lung adenocarcinoma. These results indicated that TOX3 is a prognostic indicator and promising immunomodulatory factor in lung adenocarcinoma. Future studies investigating the role of TOX3 in lung cancer immunity are warranted.
Introduction
The development of targeted therapy has resulted in improved lung cancer treatment over the past decade (1, 2) . Recently, with the identification of immunity-associated targets such as programmed death-1 receptor (PD-1), PD-ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4), as well as the development of novel immunotherapy agents, lung cancer treatments have improved notably in terms of disease control and survival outcomes (3) . However, the success rate of immunotherapy remains low, and a large number of cancer types, including lung cancer, remain largely insensitive or refractory to PD-1, PD-L1 and CTLA4 blockade (2, (4) (5) (6) . Therefore, research has focused on identifying novel immunotherapy targets or immunomodulatory factors that can be exploited to enhance the response to current immunotherapeutic agents and address immunotherapy resistance in cancer (7, 8) .
Thymocyte selection-associated high mobility group box factors (TOXs) are members of an evolutionarily conserved DNA-binding protein family, and are expressed in several immune-relevant cell subsets (9) . Increasing evidence has demonstrated that TOX gene family members are aberrantly expressed or mutated in various human diseases, particularly in malignancies, such as breast cancer (10) . For example, studies showed that TOX3 had a strong correlation with the development of breast cancer (11) . TOXs have been reported to serve a pivotal role in malignant cluster of differentiation 4-positive T cell development and are overexpressed in cytotoxic T cell lymphoma (12) . A previous study by Tessema et al (13) demonstrated that TOX1 is hypermethylated in breast cancer tissues but not in adjacent normal tissues, indicating that TOX1 may be a novel tumor biomarker. Additionally, it was reported that TOX2 is unmethylated in normal cells, while it was methylated in lung and breast tumors (13). Zhang et al (14) reported that TOX3 rs3803662 is associated with a significantly favorable prognosis in patients with diffuse-type gastric cancer. Using co-expression analysis of long non-coding RNAs and mRNAs in breast cancer, Wu et al (15) proposed that TOX4 is correlated with breast tumorigenesis and clinical outcomes. Nevertheless, the prognostic value and potential roles of individual TOX family members in lung cancer remain to be fully characterized.
In the present study, large databases were evaluated in order to determine the prognostic value of different TOX family members in lung cancer. The results indicated that characterizing the TOX expression status in patients with lung cancer may be valuable for diagnostic and prognostic assessment, as well as guiding the management of lung cancer treatment in the future.
TOX3 is a favorable prognostic indicator and potential immunomodulatory factor in lung adenocarcinoma
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Materials and methods
Oncomine analysis. The expression of TOX family members mRNA in different cancer types was determined by analyzing the Oncomine database (www.oncomine.org), which is an online, publicly accessible cancer microarray database aimed to facilitate the identification of potential target genes based on genome-wide expression analyses (16, 17) .
In the present study, Student's t-test was used to generate a P-value for comparisons between cancer specimens and normal control datasets. The fold-change was defined as ≥2 and P-value of <0.01 was used as the cut-off point, as described in our previous study (18) .
Kaplan-Meier plotter survival analysis.
The prognostic values of those TOX family members that were observed to be highly expressed in lung samples were further assessed by displaying the corresponding first progression (FP) and overall survival (OS) curves using Kaplan-Meier plotter (www.kmplot.com). The log-rank P-value was calculated and depicted on the webpage (19) .
Correlation analysis using cBioPortal for cancer genomics.
Correlations between the expression of TOX family members and that of PD-1, PD-L1 and Hepatitis A virus cellular receptor 2 (HAVCR2) in lung cancer were analyzed using the cBioPortal database (http://www.cbioportal.org/index.do) (20) . Lung adenocarcinoma [The Cancer Genome Atlas (TCGA), Provisional] and lung squamous cell carcinoma (TCGA, Provisional) datasets were used (cbioportal.org/datasets). Data are presented as the mean ± standard error of the mean. Correlation coefficients between mRNA levels were obtained through Pearson's correlation analysis. Statistical analysis was performed using SPSS 23.0 (IBM Corp., Armonk, NY, USA), and P<0.05 was considered to indicate a statistically significant difference.
Results
mRNA expression patterns of TOX family members in human lung cancer. To date, four TOX family members (TOX1-4) have been identified in human cancer types (10) . In the present study, Oncomine analysis was used to investigate the differences in mRNA expression profiles of these four TOXs between tumor and normal tissues in various types of cancer. As depicted in Fig. 1 , the database contained a total of 429, 273, 382 and 416 unique analyses for TOX1, TOX2, TOX3 and TOX4, respectively. A total of three studies demonstrating a significant increase in mRNA expression levels for TOX1 in lung cancer, compared with normal tissues, were found. For TOX2, all five datasets revealed significantly increased levels of TOX2 in normal tissues, compared with the lung cancer tissues. A total of nine analyses reported increased expression of TOX3 in tumors, while only one study reported a significant decrease in TOX3 expression in tumors, compared with normal tissues. These data indicate that TOX1 and TOX3 mRNA expression is significantly increased in lung cancer, compared with normal tissues (Fig. 1) .
TOX3 is exclusively overexpressed in lung adenocarcinoma.
Oncomine analysis revealed that, among all the TOXs, TOX3 was significantly upregulated in lung adenocarcinoma, compared with normal samples across a wide variety of datasets. The dataset from the study by Stearman et al (21) revealed that TOX3 is elevated 12.617-fold in lung adenocarcinoma samples, compared with normal samples (P=2.17x10 -7 ; Fig. 2A ). Furthermore, Landi et al (22) observed that TOX3 is overexpressed 4.968-fold in adenocarcinoma samples, compared with normal lung tissues (P=2.800x10 -18 ; Fig. 2B ). In another dataset with 246 samples from the study by Garber et al (23) , TOX3 expression was increased 8.685-fold in adenocarcinoma, compared with normal lung tissue (P=1.180x10 -22 ; Fig. 2C ). The expression profiles of TOX1 were varied in other pathological subtypes of lung cancer. In small cell lung cancer and lung carcinoid tumor, TOX1 expression was 5.591 and 11.468 times increased, compared with normal lung tissue, respectively ( Fig. 2D and E) (19) . Another dataset from the study by Hou et al (24) demonstrated that TOX1 expression was 3.416 times increased in large cell lung carcinoma, compared with lung adenocarcinoma (Fig. 2F ). ) and TOX4 ( Fig. 3D; HR=0 ) and TOX4 ( Fig. 3H ; HR=0.670; P=3.400x10 -10 ) mRNA expression. These data revealed that elevated TOXs expression predicted improved prognosis in patients with lung cancer, indicating that TOXs potentially act as tumor suppressors in lung cancer.
Elevated TOXs expression predicts longer survival time in
Elevated TOX3 expression is associated with distinctive survival outcomes in lung adenocarcinoma. Subsequently, the prognostic significance of each TOX was stratified by a number of default clinicopathological parameters, including smoking status and chemotherapy status, in the Kaplan-Meier plotter database was examined. The prognostic effects of the four genes are detailed in Tables I and II. The results revealed that high TOX3 mRNA expression was significantly associated with improved FP in a subgroup of patients who had never smoked (HR=0.370; P=7.500x10 -5 ; Table I ). By contrast, high mRNA TOX4 expression was significantly associated with improved FP both in patients with smoking (HR=0.730; P=0.012) and without smoking history (HR=0.560; P=0.018) (Table I) . Notably, the present data also demonstrated that high levels of TOX3 mRNA were significantly associated with increased OS in patients who had received chemotherapy (HR=0.580; P=8.200x10 -3 ; Table II ), indicating a potential role of TOX3 in the chemosensitivity of lung cancer. Notably, the present results revealed that high TOX3 mRNA expression is significantly associated with improved FP (HR=0.600; P=1.300x10 
High mRNA expression of TOX3 is correlated with low mRNA expression of PD-1, PD-L1 and HAVCR2 in lung adenocarcinoma.
To further investigate the role of TOX3 in lung adenocarcinoma, the cBioPortal database was used to analyze the correlation between TOX3 and various immunotherapy target genes. Gene correlation analysis demonstrated that, in lung adenocarcinoma, high expression of TOX3 was correlated with low expression of PD-1 ( Fig. 5A ; r=-0.142; P=0.001), PD-L1 ( Fig. 5C ; r=-0.228; P<0.001) and HAVCR2 ( Fig. 5E ; r=-0.198; P<0.001). However, in squamous cell carcinoma, no significant correlation was observed between TOX3 and PD-1 ( Fig. 5B ; r=-0.017; P=0.696), PD-L1 ( Fig. 5D ; r=0.004; P=0.930) or HAVCR2 ( Fig. 5F ; r=-0.039; P=0.384) expression.
Discussion
Immunotherapy is increasingly being recognized as a key treatment for patients with lung cancer (8) . The identification of novel immunomodulatory targets or factors is expected to aid a subset of patients with lung cancer, particularly those who do not benefit from the current therapy targeting immune checkpoint molecules, including PD-1, PD-L1 and CTLA-4 (25, 26) .
TOX is novel gene family that serves a pivotal function in human immunity (9) . Recently, deregulated expression of TOX family members has been reported in a wide range of human cancer types (10) . For example, Seksenyan et al (27) reported two different roles for TOX3, one in the initiation of breast cancer, potentially associated with expression of TOX3 in mammary epithelial cell progenitors, and another role in the progression of cancer. Additionally, emerging studies indicated that, by monitoring TOX status in an individual tumor, the risk of cancer development and progression could be predicted, as could prognosis (14, 28) . However, the potential roles and prognostic values of different TOX members remain to be fully clarified.
Through systematic and in-depth investigation of a series of databases, the present study identified the expression patterns of various TOX family members in lung cancer, and provided evidence to support their potential functions in lung cancer. Analysis of the Oncomine database indicated that, among all TOX members, TOX1 and TOX3 were significantly highly expressed in lung cancer, compared with normal controls, indicating important roles for these molecules in lung cancer. In a genome-wide comparison of DNA methylation between normal and tumor cells performed in a previous study, it was indicated that TOX1 was silenced through CpG hypermethylation in lung cancer, which provides a possible mechanism for the development of lung cancer (13) . The TOX3 gene is reported to be frequently absent in breast cancer, and has recently been demonstrated to be a risk factor for breast cancer (29) . However, the role of TOX3 in lung cancer remains to be elucidated. In the present study, the analysis of several individual datasets derived from Oncomine revealed that TOX3 was exclusively overexpressed in lung adenocarcinoma. Further survival analysis with Kaplan-Meier plotter revealed that high levels of TOX3 mRNA were significantly associated with increased FP and OS in patients with lung adenocarcinoma. Based on these results, it was extrapolated that TOX3 may serve a tumor-suppressive role in lung cancer. This hypothesis was supported by Riaz et al (30) , who indicated that TOX3 may act as a tumor-suppressor gene, as the risk allele rs3803662 was significantly associated with low TOX3 expression in breast cancer. Additionally, TOX3 knockdown increased cell proliferation in breast cancer. In addition, the TOX3 rs3803662 CT/TT genotype was associated with improved survival in patients with diffuse-type gastric cancer, acting as an independent prognostic marker (14) . Notably, to the best of our knowledge, the present study is the first to report that high TOX3 transcription levels predict improved survival in patients with lung cancer who have received chemotherapy. It was hypothesized that TOX3 may be an important indicator of chemosensitivity in lung cancer.
In the past few years, emerging evidence pertaining to the association between the immune system and cancer has contributed to our understanding of the human immune system, which can eradicate cancer cells when properly stimulated (31) . To date, the best characterized and most clinically studied immune checkpoints are PD-1, PD-L1 and CTLA-4 (32,33). The PD-1 receptor is expressed on the surface of cells involved in the antitumor immune response (34) . When its high-affinity ligand PD-L1 binds to the PD-1 receptor, the receptor complex activation induces intracellular inhibitory signaling cascades that result in dysfunctional tumor-infiltrating T cells (28) . These T cells have exhibited poor proliferation and a reduced capacity to produce cytokines (32) . PD-L1 tumor expression and pre-existing tumor T-cell infiltration have been correlated with improved clinical outcomes to anti-PD-1/anti-PD-L1 (35) . Identifying genes or co-factors associated with these immunotherapy targets could increase our knowledge of immunotherapy and aid the identification of novel immunotherapeutic targets.
Correlation analysis using the cBioPortal database revealed that TOX3 is negatively correlated with PD-1, PD-L1 and HAVCR2 in lung adenocarcinoma. However, no significant correlation was observed between TOX3 and PD-1, PD-L1 or HAVCR2 in the squamous cell carcinoma subtype. PD-L1 expression has been recognized as the most important biomarker for predicting the treatment response of immunotherapy in lung cancer (4) . The strong correlation between TOX3 and PD-L1 expression was in line with the prognostic value of TOX3 in lung adenocarcinoma, and indicated that TOX3 may serve as an immunomodulatory co-factor with a suppressive role in the development of lung adenocarcinoma.
HAVCR2, also known as Tim-3, is a newly identified immunity regulator that was reported to be ubiquitously expressed in multiple tumor cells and T cells (36) . Similar to PD-1, HAVCR2 is also one member of inhibitory checkpoint molecules (37) . HAVCR2 protein negatively regulates Th1/Tc1 function by inducing cell death upon interaction with its ligand, galectin-9 (38) . It has been demonstrated in previous studies that in vivo HAVCR2 blockade with other checkpoint inhibitors enhances antitumor immunity and suppresses tumor growth in a number of preclinical tumor models, which strongly indicate a potential role in tumor progression (39, 40) . In the present correlation analysis, it was observed that TOX3 expression is negatively associated with HAVCR2 in lung adenocarcinoma. However, no significant correlation between TOX3 and HAVCR2 expression was detected in the squamous cell carcinoma subtype. This was consistent with the prognostic values of TOX3, which are conversely associated with HAVCR2 expression, indicating the tumor-suppressive role of TOX3 in lung adenocarcinoma.
In summary, ectopic TOX expression is common in lung cancer. In particular, elevated TOX3 expression defines a subgroup of patients with lung adenocarcinoma and predicts improved survival outcomes. Furthermore, TOX3 expression is negatively correlated with the immunotherapy targets PD-1, PD-L1 and HAVCR2 in lung adenocarcinoma, indicating that it serves a role in immunity activation. Analyses of TOX family members in a variety of databases, particularly those focused on their association with immunotherapeutic targets, offer a novel insight into the role of TOXs in lung cancer and provides a theoretical basis for future research in this field.
